SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial
5 references·2 citing·34 second hop
Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial (2007)Cost-effectiveness of trastuzumab in the …Methods for the Economic Evaluation of Health Care Programmes (2005)Methods for the Economic Eval…A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis (2005)A monoclonal antibody against…Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge? (2004)Use of Cost-Effectiveness Ana…Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness (1995)Five‐Hundred Life‐Saving Inte…The Markov Process in Medical Prognosis (1983)The Markov Process in Medical…Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force (2013)Consolidated Health Economic …Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial (2011)Short-course adjuvant trastuz…Where Now for Saving Lives? (1976)Value of a Life: What Difference Does It Make?1 (1981)Trust, Emotion, Sex, Politics, and Science: Surveying the Risk‐Assessment Battlefield (1999)The RAND-36 measure of health-related quality of life (2001)The Value of a Statistical Life: A Critical Review of Market Estimates Throughout the World (2003)An Introduction to Markov Modelling for Economic Evaluation (1998)Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer (2007)Health related quality of life in different states of breast cancer (2007)How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)Cost-Effectiveness in Health and Medicine (1996)Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Bias in published cost effectiveness studies: systematic review (2006)Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold (2008)What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? (2008)Cost-effectiveness analysis. (1993)Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment (2002)HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis (2004)An economic evaluation of Herceptin® in adjuvant setting: the Breast Cancer International Research Group 006 trial (2005)Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis (2006)Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer (2008)Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement (2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. (2009)Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement (2013)Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement (2016)XXIV. On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies. In a letter to Francis Baily, Esq. F. R. S. &c (1825)A Population Study. (1975)A convenient approximation of life expectancy (the “DEALE”) (1982)Markov Models in Medical Decision Making (1993)The Beaver Dam Health Outcomes study (1993)Decision Making in Health and Medicine: Integrating Evidence and Values (2001)The estimation of a preference-based measure of health from the SF-36 (2002)Systematic reviews: CRD's guidance for undertaking reviews in health care (2010)Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)
this work references cited by second hop

References

  • 2005Methods for the Economic Evaluation of Health Care Programmes13,647 cited
  • 1995Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness1,318 cited
  • 1983The Markov Process in Medical Prognosis957 cited
  • 2004Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?790 cited
  • 2005A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis58 cited

Cited by

  • 2013Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force2,025 cited
  • 2011Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial50 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work